Pharma Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business & Finance
Biopharmaceutical company reports underwriter exercise of over-allotment option
August 15th, 2005
Keryx Biopharmaceuticals, Inc. (KERX) announced that on July 15, 2005, the underwriters exercised in full their over-allotment option to purchase 750,000 shares of common stock at a public offering price of $14.05 per share. The closing of the purchase of the over-allotment shares took place simultaneously with the initial sale of 5,030,000 shares, for a total of 5,780,000 shares of common stock sold in the offering by Keryx, resulting in gross proceeds, before commissions and expenses, of $81.2 million. J.P. Morgan Securities Inc. acted as the sole book-running manager in this offering and Bear, Stearns & Co. Inc. acted as co-lead manager. Jefferies...
Source: Pharma Business Week (2005-08-15)
|
